

University of Mississippi

eGrove

Annual Poster Session 2022

Annual Poster Session

10-11-2022

Employing Hot-Melt Extrusion Technology to Enhance the Solubility of Cannabidiol (CBD)

Iman Taha

University of Mississippi, itaha@go.olemiss.edu

Mahmoud A. ElSohly

University of Mississippi

Mohamed M. Radwan

University of Mississippi

Sundus H. Omari

University of Mississippi

Michael A. Repka

University of Mississippi

See next page for additional authors

Follow this and additional works at: https://egrove.olemiss.edu/pharm_annual_posters_2022

Recommended Citation

Taha, Iman; ElSohly, Mahmoud A.; Radwan, Mohamed M.; Omari, Sundus H.; Repka, Michael A.; and Ashour, Eman A., "Employing Hot-Melt Extrusion Technology to Enhance the Solubility of Cannabidiol (CBD)" (2022). *Annual Poster Session 2022*. 21.

https://egrove.olemiss.edu/pharm_annual_posters_2022/21

This Book is brought to you for free and open access by the Annual Poster Session at eGrove. It has been accepted for inclusion in Annual Poster Session 2022 by an authorized administrator of eGrove. For more information, please contact egrove@olemiss.edu.

Authors

Iman Taha, Mahmoud A. ElSohly, Mohamed M. Radwan, Sundus H. Omari, Michael A. Repka, and Eman A. Ashour

Employing Hot-Melt Extrusion Technology to Enhance the Solubility of Cannabidiol (CBD)

Iman E. Taha¹, Mahmoud A. ElSohly^{1,2}, Mohamed M. Radwan², Sundus H. Omari¹, Michael A. Repka^{1,3}, Eman A. Ashour¹

¹Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS 38677, USA.

²National Center for Natural Products Research, School of Pharmacy, University of Mississippi, University, MS 38677, USA.

³Pii Center for Pharmaceutical Technology, University of Mississippi, University, MS 38677, USA.

PURPOSE

Cannabidiol (CBD) is a non-psychoactive cannabinoid isolated from *Cannabis sativa*. It has been reported that CBD has anticonvulsant, anxiolytic, antipsychotic, and anti-inflammatory effects and was approved by the FDA as a treatment of epilepsy in pediatric. Despite the many pharmacological potentials of CBD, its drawbacks have limited its applications in therapeutics. Poor water solubility is the major drawback in addition to the first-pass metabolism and thus low bioavailability (approximately 6%). The primary purpose of the current project was to enhance the CBD bioavailability by improving its solubility and avoid the effect of first-pass metabolism using Hot-Melt Extrusion technology.

OBJECTIVE

The main objective of this project was to develop CBD muco-adhesive buccal film using HME in order to improve the water solubility, avoid the first pass metabolism and therefore enhance the CBD bioavailability.

METHODS

Different formulations were developed by mixing 10% w/w CBD with polymeric carrier/s and other excipients (Table 1). The resulted physical mixtures were fed into a Thermo Scientific HAAKE Mini lab II (Thermo Fisher Scientific) and a film die (1 mm thickness) was used to produce the CBD films. Differential scanning calorimetry DSC (TA DSC 25) was performed for CBD, the polymeric carriers and the extruded films to determine their thermal characterization. Samples were weighed in T-zero pans (3–5 mg). The temperature was elevated from 25 to 200 °C at a rate of 10 °C/min under a flow of ultrahigh purity nitrogen gas. CBD drug content and content uniformity were evaluated by HPLC. Bio-adhesion test was performed using a texture analyzer (TA-XT2) to evaluate the adhesiveness properties of each film. Solubility studies were performed for the developed films and the pure CBD using the shake-flask method at room temperature for 48 hours to evaluate the improvement of CBD solubility in the HME films. A drug release study was performed using a multi-position Stirring Hot Plate. The dissolution media used was 100 mL of simulated saliva (pH 6.8), 0.1 % w/v SLS at 37 ± 0.5 °C. Samples withdrawal were at 15, 30, 60, 90, 120, 180 and 240 minutes for analysis using HPLC.

RESULTS

- The drug content in all the formulations was in the range of 93.6 - 103%.
- The DSC results show melting peaks at 69 °C and 65 °C for CBD and PEO N80 respectively. The CBD endothermic peak disappeared in all prepared HME films indicating the transformation of CBD from crystalline to amorphous state (Figure 1).
- The bio-adhesion results (Table 2) demonstrated higher adhesiveness for the formulation containing PEO N80 and carbopol compared to other formulations.
- The solubility studies showed an enhancement in CBD solubility for all HME buccal films (Figure 2). The CBD water solubility showed 125.60, 307.56, 318.22, and 362.72 µg/mL for formulations **F4**, **F6**, **F7**, and **F8** respectively. While the pure CBD water solubility was below the LOD of the analytical method.
- The drug release studies, as shown in Figure 3 showed significant enhancement in the CBD release in formulations **F4**, **F6**, **F7** and **F8** (2 to 5 fold) compared to the pure CBD.




Figure 1. DSC Thermogram of CBD, polymers, and HME films (F1, F2, F3, F4, F5, F6, F7, and F8)




Figure 2. CBD water solubility in µg/mL for F4, F6, F7, F8, and pure CBD.

Table 1. HME buccal film formulation composition

	PEO-N80 % w/w	Klucel™ EF % w/w	SOLUPLU S % w/w	TPGS % w/w	SLS % w/w	CBD % w/w	Carbopol 980 % w/w	Carbopol 934 % w/w
F1	68	0	10	0	2	10	0	10
F2	75	0	10	5	0	10	0	0
F3	0	75	10	5	0	10	0	0
F4	0	68	10	10	2	10	0	0
F5	30	38	10	10	2	10	0	0
F6	75	0	0	5	0	10	10	0
F7	75	0	0	5	0	10	0	10
F8	85	0	0	5	0	10	0	0

Table 2 Ex-vivo adhesion results for CBD mucoadhesive buccal films

	peak force N	Adhesiveness N.mm	work of adhesion	Stringiness mm
F1	0.774	1.095	0.183	0.412
F2	0.670	0.726	0.061	0.221
F3	0.839	0.977	0.131	0.276
F4	0.565	0.781	0.078	0.208
F5	0.221	1.060	0.034	0.182
F6	0.846	1.663	0.258	0.512
F7	1.276	1.607	0.423	0.591
F8	0.944	1.126	0.320	0.637




Figure 3. release study profiles for f4, f6, f7 and f8 and pure CBD

CONCLUSION

Successfully mucoadhesive buccal films have been developed using HME technology. The results of this study showed an enhancement of the solubility and drug release of CBD. This finding supports that the developed formulations promise to enhance the CBD bioavailability.

REFERENCES

- Moltke J, Hindocha C. Reasons for cannabidiol use: a cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems. *Journal of cannabis research*. 2021 Dec;3(1):1-2.
- Mannila J, Järvinen T, Järvinen K, Jarho P. Precipitation complexation method produces cannabidiol/β-cyclodextrin inclusion complex suitable for sublingual administration of cannabidiol. *Journal of pharmaceutical sciences*. 2007 Feb 1;96(2):312-9.
- Langley N, DiNunzio J, Repka MA. *Melt Extrusion: Materials, Technology and Drug Product Design (AAPS Advances in the Pharmaceutical Sciences Series)*. Springer; 2013.
- Thakkar R, Thakkar R, Pillai A, Ashour EA, Repka MA. Systematic screening of pharmaceutical polymers for hot melt extrusion processing: A comprehensive review. *International journal of pharmaceutics*. 2020 Feb 25;576:118989